Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promethera Bio, EMD Millipore to Develop a Liver Pharmaco-Toxicological Assay

Published: Tuesday, March 11, 2014
Last Updated: Tuesday, March 11, 2014
Bookmark and Share
Companies collaborate to develop an improved ready-to-use microfluidic perfusion liver assay.

This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism. Early availability of reliable human liver-based assays is critical to the pharmaceutical industry when deciding to bring a lead compound in clinical phase development. 

With their combined expertise and synergies, the companies are well positioned to develop a ready-to-use long-term liver-based assay. The Promethera Biosciences team is specialized in isolating, expanding and characterizing human liver progenitor cells for both cell therapy and liver cell based assays. EMD Millipore is a global life science company with an extensive portfolio of cell analysis instruments, research reagents and assays, cell culture and sample preparation products, plus advanced microfluidic cell culture as well as drug discovery services. 

Promethera Biosciences has identified a novel adult human hepatic progenitor cell population that can be maintained in vitro in two-dimensional and three-dimensional cell culture conditions providing new models for testing in vitro drug metabolism: Promethera H2Screen and H3screen. This technology is the object of a patent application filed by Promethera Biosciences. There are various benefits with this new technology; Promethera Biosciences cell-based models are derived from healthy human livers and acquire a metabolic capacity within the range of primary hepatocytes. They have long-term stability in culture as well as potential for large-scale production and reproducibility across batches. 

EMD Millipore’s ‘Pearl’ microfluidic technology maintains hepatocyte functionality by mimicking the liver microenvironment. When liver cells are cultured in the ‘Pearl’ format they recover key metabolic functions and could display phenotypic profiles of the intact organ for over a month. 

The project for developing a new product combining the strengths of EMD Millipore 'Pearl' microfluidic technology and of Promethera Biosciences H2Screen/H3Screen cells has been selected by the Belgian Walloon Region Biocluster (BioWin) and the Massachusetts Life Sciences Center (MLSC). It will be funded 900K€ in total for both partners. 

The Belgian Walloon region and the Massachusetts Life Sciences Center (MLSC) are partners in the International Collaborative Industry Program (ICIP). The program’s objective is to promote and motivate collaboration between life sciences companies in Massachusetts (USA) and other countries by facilitating partnerships, supporting exciting new projects, and providing joint funding for helping to swiftly design and develop innovative products and services. 

In April 2013 a call was launched with four partner foreign regions of the Massachusetts Life Sciences Center in the ICIP program. Promethera Biosciences and EMD Millipore were one of the four collaborative projects selected by independent Belgian and American panels of experts. 

”We are very pleased to initiate this collaboration with EMD Millipore and to combine our expertise to develop a ready to use liver based assay. We sincerely thank the Walloon region and the MLSC for funding this innovative project”, said Eric Halioua, Chief Executive Officer of Promethera Biosciences. 

“The opportunity to work closely with Promethera over the course of the project, speaks to the nature of our organization: enabling our partners to conduct potentially life-saving research,” says Robert Yates, President and CEO of EMD Millipore. “We are looking forward to building our relationship and more importantly to the outcomes this partnership has the potential to deliver. A sincere thanks to the MLSC for the opportunity to see what this collaboration can achieve and more importantly the continued support of the Massachusetts Life Sciences industry.” 

An urgent need for reliable human liver-based assays for early preclinical testing 
Early availability of reliable human liver-based assays is critical to the pharmaceutical industry in deciding to bring a lead compound in clinical phase development. 30% of drug candidates fail during clinical development due to toxicity issues. Hepatocyte (liver cells) based studies represent 85% of in vitro toxicology assays. But current models are limited by key technological challenges such as long-term stability of hepatic functionality to allow chronic toxicity testing, and obtaining a stable and consistent human cell source at acceptable cost. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promethera® Biosciences Reshapes its Leadership Team
Company announces resignation of Eric Halioua from his post as CEO of Promethera.
Saturday, January 24, 2015
Promethera Appoints Dr John Tchelingerian as the New Chairman of the Board
John Tchelingerian, PhD, a well-recognized biotech entrepreneur, brings scientific, deal making and commercial experience to the team.
Tuesday, December 30, 2014
Promethera Biosciences Raises €25.33 Million in Series C Financial Round
Promethera Biosciences raises €20.33 million in capital and €5 million in loans and subsidies from the Walloon region (Belgium).
Thursday, November 27, 2014
Promethera Receives Approval to Enroll Patients in the Imminent HEP002 Phase IIb/III Clinical Trial
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients.
Thursday, October 16, 2014
Promethera Biosciences Announces CFO
Frank Hazevoets joined the Company on May 1, 2014 as chief financial officer.
Tuesday, May 13, 2014
Promethera Successfully Enrolls Twenty Patients in its Multicentric Phase I/II Trial
Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, treating twenty patients affected by very rare liver-based metabolic diseases.
Tuesday, November 12, 2013
Promethera Biosciences Opens the French Part of its Clinical Trial in Cell Therapy
Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hospital Jeanne de Flandre, Lille, France.
Thursday, February 28, 2013
Promethera Biosciences Treats First Patients with Promethera® HepaStem
Phase I/II study designed to evaluate the ability of liver progenitor cells to restore a missing enzyme function in liver-based metabolic diseases.
Tuesday, May 15, 2012
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!